Immunotherapy before surgery for HPV-related throat cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests whether giving the drug atezolizumab before surgery can help shrink HPV-related throat cancer and improve outcomes. Atezolizumab helps your immune system fight cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have HPV-related throat cancer that is considered early-stage and can be removed with surgery
- You have not had radiation therapy above the collarbone before
- You are in generally good health, with adequate organ function
- You are willing to use effective contraception if sexually active
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new nasal vaccine combined with an immunotherapy drug (tislelizumab) given before surgery for people with HPV-positive oropharyngeal cancer. The goal is to help the immune system fight the cancer and potentially improve outcomes after surgery.
This trial tests whether a combination of immunotherapy and chemotherapy before surgery can help people whose throat cancer has come back after treatment. The goal is to shrink the tumor before surgery, which may improve outcomes.
This trial tests whether giving a combination of an immunotherapy drug (PD-1 inhibitor) and chemotherapy before surgery can help treat advanced throat cancer. The goal is to see if this approach shrinks tumors and improves outcomes.
This Phase 2 trial studies whether 5-azacytidine and nivolumab (alone and/or together) can work well and be tolerated in people with HPV-related throat cancer that can be surgically removed. The goal is to help shrink or control the cancer before resection and learn more from added tumor samples.
This trial compares standard chemotherapy alone versus chemotherapy combined with an investigational vaccine (PRGN-2009) before surgery for newly diagnosed HPV-positive oropharyngeal (throat) cancer. The goal is to see if adding the vaccine improves outcomes.
This trial tests whether giving less radiation after surgery is safe and effective for people with early-stage HPV-related throat cancer. It aims to reduce side effects while still controlling the cancer.
Hear when a new Oropharynx Cancer, Stage I trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.